Applicant: Wolfram Eichner et al. Attorney's Docket No.: 14503-0005US1

Serial No.: 10/567,266 Filed : May 29, 2008

Page : 2 of 14

## Amendments to the Claims

No amendments to the claims are presented herein. The following listing is for the Examiner's convenience.

## Listing of Claims

1. (Withdrawn) A method for preparing a conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), the method comprising reacting at least one functional group A of the polymer or the derivative thereof with at least one functional group Z of the protein and thereby forming a covalent linkage, wherein Z is selected from the group consisting of an aldehyde group and a keto group, and

$$H_2N$$

wherein A is a hydrazido group

forming said linkage with Z, and wherein G

- 2. (Withdrawn) The method as claimed in claim 1 wherein the hydroxyalkyl starch is hydroxyethyl starch.
- 3. (Withdrawn) The method as claimed in claim 2 wherein the hydroxyethyl starch has a molecular weight of from 2 to 200 kD.
- 4. (Cancelled)

is O or S.

- 5. (Withdrawn) The method as claimed in claim 1, wherein the aldehyde group or the keto group is located in a carbohydrate side chain of the protein and/or at the N-terminal group of the protein.
- 6. (Withdrawn) The method as claimed in claim 5, further comprising oxidizing the carbohydrate side chain of the protein and/or oxidizing the N-terminal group of the protein to give the aldehyde group or keto group.

Applicant: Wolfram Eichner et al. Attorney's Docket No.: 14503-0005US1

Serial No.: 10/567,266 Filed: May 29, 2008 Page: 3 of 14

- 7. (Withdrawn) The method as claimed in claim 6, wherein the oxidation reaction is carried out enzymatically or using a periodate, in each case, if necessary, after having removed a terminal sialic acid.
- 8. (Withdrawn) The method as claimed in claim 1, further comprising reacting the polymer at its non-oxidized reducing end with an at least bifunctional linking compound comprising a functional group capable of reacting with the non-oxidized reducing end of the polymer and the group A, prior to the reaction of the polymer derivative comprising A and the protein comprising Z.
- 9. (Cancelled)
- 10. (Withdrawn) The method as claimed in claim 8, wherein the at least bifunctional linking compound is a homobifunctional compound.
- 11-12. (Cancelled)
- 13. (Withdrawn) The method as claimed in claim 8, wherein the reaction of the polymer with the at least bifunctional linking compound is carried out in an aqueous medium.
- 14-53. (Cancelled)
- 54. (Withdrawn) A conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

HAS' 
$$OR_1$$
  $OR_2$   $OR_3$   $OR_3$   $OR_4$   $OR_3$   $OR_4$   $OR_5$   $OR_5$   $OR_6$   $OR_7$   $OR_8$   $OR$ 

Applicant: Wolfram Eichner et al. Attorney's Docket No.: 14503-0005US1

Serial No.: 10/567,266 Filed: May 29, 2008 Page: 4 of 14

and/or

wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, wherein G is selected from the group consisting of O and S, and wherein L is an optionally suitably substituted, linear, branched and/or cyclic hydrocarbon residue, optionally comprising at least one heteroatom having from 2 to 60 carbon atoms.

- 55. (Withdrawn) The conjugate as claimed in claim 54,wherein -L- is - $(CH_2)_n$  with n = 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- 56. (Previously Presented) A conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

and/or

Applicant: Wolfram Eichner et al. Attorney's Docket No.: 14503-0005US1

Serial No.: 10/567,266 Filed: May 29, 2008 Page: 5 of 14

HAS' 
$$R_2O$$
  $R_3$   $R_3O$   $R_3$   $R_4$   $R_5$   $R_5$   $R_6$   $R_7$   $R_8$   $R_8$ 

wherein  $R_1$ ,  $R_2$  and  $R_3$  are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, and wherein G is selected from the group consisting of O and S.

## 57-71. (Cancelled)

- 72. (Previously Presented) The conjugate as claimed in claim 54 or claim 56, wherein the hydroxyalkyl starch is hydroxyethyl starch.
- 73. (Previously Presented) The conjugate as claimed in claim 72 wherein the hydroxyethyl starch has a molecular weight of from 2 to 200 kD.
- 74. (Cancelled)
- 75. (Previously Presented) A pharmaceutical composition comprising in a therapeutically effective amount a conjugate as claimed in claim 54 or claim 56.
- 76. (Original) A pharmaceutical composition as claimed in claim 75, further comprising at least one pharmaceutically acceptable diluent, adjuvant, or carrier.
- 77. (Withdrawn) A method for treatment of a disorder characterized by a reduced hematopoietic or immune function, comprising administering to a subject in need thereof a therapeutically effective amount of the conjugate as claimed in claim 54 or claim 56.
- 78. (Withdrawn) The method as claimed in claim 77, wherein the disorder is a result of chemotherapy, radiation therapy, infectious disease, severe chronic neutropenia, or leukemia.